Psr1 Cost-Effectiveness of Clopidogrel Versus Aspirin in the Prevention of Ischemic Events in Stroke and Tia Patients: A Four-European Country Analysis

Palmer, AC; Roze, S; Hankey, Graeme J.; Hakimi, Zalmaï; Spiesser, J; Carità, Patrizia; Gabriel, S

doi:10.1016/s1098-3015(10)62878-1

Cited by 1 publication

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 34 potentially relevant studies, 11 [69][70][71][72][73][74][75][76][77][78][79] met the criteria for inclusion in the cost-effectiveness review; one study 69 was also included in the SR that informed the previous guidance. 24 Of the 11 [69][70][71][72][73][74][75][76][77][78][79] included studies, seven [69][70][71][72][73][74][75] were published in full, whereas four 76-79 were available only in an abstract format. Most of the studies were of reasonable quality; however, more detail and focused critique of the clinical effectiveness evidence used to inform the economic evaluations would have improved the quality of the studies (see Appendix 2).…”

Section: Review Of Existing Cost-effectiveness Studiesmentioning

confidence: 99%

“…Five 69,71,72,74,76 of the 11 69-79 studies included were described as cost-effectiveness analyses and six 70,73,75,[77][78][79] as cost-utility analyses. The cost-effectiveness analyses have used a range of health outcomes including life saved, events avoided, life-years lived, time spent free of stroke recurrence or disability and life expectancy.…”

Section: Characteristics Of Economic Evaluationsmentioning

confidence: 99%

“…The mean age varied according to the trial source used, ranging from 60 to 70 years. Only four studies 70,73,77,78 described a UK population. Most of the studies adopted a lifetime perspective; however, four 69,71,72,77 adopted a short-term perspective (e.g.…”

Section: Characteristics Of Economic Evaluationsmentioning

confidence: 99%

“…74,75 Costs of acute events, including hospitalisations and acute care, have been taken from the trial-based papers, 71,73 Medicare diagnosis-related groups data, 74,75 NHS Trust Financial Return data 70 and the published literature. 71,78 Only three papers 76,77,79 do not state the sources of the cost data used. All papers but one 74 have mentioned a discount rate for costs, as Table 29 shows.…”

Section: Cost Data and Cost Sourcesmentioning

confidence: 99%

“…Efficacy data and data sources Only Palmer et al 77 and Stevenson et al 78 present data related to efficacy; the rest of the studies only point out that efficacy data are taken from a specific trial. Health outcome data and data sources Six of the economic evaluations used QALYs as the main measure of health outcome; other outcomes include life-years saved and life expectancy.…”

Section: Cost Data and Cost Sourcesmentioning

confidence: 99%

See 4 more Smart Citations

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis

Greenhalgh

Bagust²,

Boland³

et al. 2011

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of project...

show abstract